NAT10 Promotes Tubular Epithelial Cell Senescence in Cisplatin-Induced Acute Kidney Injury by Regulating DDX17

Yuting Zhu, Wenchao Xu, Cheng Wan, Bowen Deng, Yaru Xie, Bin Yang, Hongyang Jiang, Chun ZhangInternational Journal of Biological Sciences 2026 · DOI

TL;DR

This study identifies N-acetyltransferase 10 (NAT10) as a key driver of cellular senescence in acute kidney injury (AKI) induced by the chemotherapy drug cisplatin. The researchers found that inhibiting NAT10 protects kidney function and reduces damage by targeting a novel pathway involving the protein DDX17, suggesting a new therapeutic avenue for AKI.

What Problem Does This Paper Address?

Acute kidney injury (AKI) is a serious condition with high mortality and limited treatment options, and its underlying mechanisms are not fully understood. Cisplatin, a common chemotherapy agent, is known to cause AKI in a significant portion of patients. Cellular senescence, a state of permanent cell cycle arrest, has recently emerged as a critical factor in AKI pathogenesis, contributing to inflammation and tissue damage. However, the specific molecular players and pathways that trigger and regulate this senescence in the context of cisplatin-induced AKI were unclear. This paper aims to elucidate the role of NAT10, a protein acetyltransferase, in this process and to uncover its regulatory mechanisms.

Methods

The researchers employed a multi-pronged approach using both in vitro (cell culture) and in vivo (mouse models) systems.

  • Animal Models: They induced AKI in mice using cisplatin and then treated them with either a NAT10 inhibitor (Remodelin) or used lentivirus to knock down NAT10 expression in the kidney.
  • Cell Culture: Human proximal tubule epithelial cells (HK-2) were used to model cisplatin-induced AKI. They utilized lentivirus-mediated knockdown of NAT10 and siRNA to silence DDX17.
  • Biochemical Assays: Standard techniques like Western blotting, qPCR, and ELISA were used to measure protein and mRNA levels of various markers related to kidney injury (NGAL, KIM-1), cellular senescence (p53, p21, p16, γ-H2A.X, SA-β-gal), and inflammatory responses (IL-1β, IL-6, TNF-α).
  • Immunohistochemistry (IHC) and Immunofluorescence (IF): These techniques were used to visualize the localization and expression of NAT10, DDX17, and senescence markers within kidney tissues and cells.
  • Co-immunoprecipitation (Co-IP) and Mass Spectrometry (MS): These were crucial for identifying direct protein-protein interactions, specifically between NAT10 and DDX17.
  • RNA Sequencing (RNA-seq): Performed to identify differentially expressed genes in response to NAT10 knockdown, providing insights into the pathways affected.
  • Oxidative Stress Assays: Dihydroethidium (DHE) staining was used to assess reactive oxygen species (ROS) levels.

Datasets

The study utilized established cell lines (HK-2) and animal models. RNA-sequencing data was generated and deposited in the NCBI's GEO database (GSE315580). No new benchmark datasets were introduced.

Key Insights and Ideas

  • NAT10 as a Key Player in Cisplatin-Induced AKI: The study strongly implicates NAT10 in promoting kidney damage and cellular senescence following cisplatin exposure.
  • NAT10 Drives Cellular Senescence: Beyond general kidney injury, NAT10 specifically appears to induce a senescent phenotype in tubular epithelial cells, characterized by cell cycle arrest and the release of inflammatory factors (SASP).
  • DDX17 is a Crucial Downstream Effector: The most significant finding is the identification of DDX17 as a direct interaction partner of NAT10. NAT10 appears to regulate DDX17 protein expression and stability, and this interaction is essential for NAT10's pro-senescence effects.
  • The NAT10/DDX17 Axis: The research proposes a novel signaling pathway where NAT10 interacts with and upregulates DDX17, leading to tubular epithelial cell senescence and subsequent AKI.
  • Therapeutic Potential of Targeting NAT10/DDX17: Inhibiting NAT10, either pharmacologically with Remodelin or genetically, shows significant renoprotective effects, highlighting this axis as a promising therapeutic target.

Key Results

  • Cisplatin treatment significantly increased NAT10 expression in both mouse kidneys and HK-2 cells.
  • Knockdown of NAT10 or treatment with the NAT10 inhibitor Remodelin ameliorated cisplatin-induced kidney dysfunction, reduced tubular injury markers (NGAL, KIM-1), and attenuated cellular senescence markers (p53, p21, γ-H2A.X, SA-β-gal).
  • NAT10 was shown to directly interact with DDX17 via co-immunoprecipitation.
  • NAT10 knockdown or inhibition led to reduced DDX17 protein levels in cisplatin-treated kidneys and cells.
  • Silencing DDX17 alone was sufficient to inhibit cisplatin-induced senescence in HK-2 cells.
  • Overexpressing DDX17 could partially rescue the protective effects of NAT10 knockdown, confirming the dependency of NAT10's action on DDX17.
  • Remodelin demonstrated a favorable safety profile in mice, with no significant toxicity observed after prolonged treatment.

Limitations and Future Work

  • Human Tissue Validation: The authors acknowledge that while mouse models and human cell lines provide robust evidence, validation in human kidney tissues would enhance clinical relevance.
  • Cell-Type Specificity: The study used lentivirus for NAT10 knockdown in the kidney cortex, but it's acknowledged that immune and other parenchymal cells might also be affected. Future studies using tubule-specific conditional knockout mice are suggested for precise definition of NAT10's role.
  • Mechanism of DDX17 Regulation: While the interaction and regulation of DDX17 by NAT10 are shown, the precise molecular mechanism (e.g., direct acetylation of DDX17 by NAT10) remains to be explored.
  • DDX17 in AKI Animal Models: The role of DDX17 in renal dysfunction and cellular senescence needs further validation in AKI animal models.
  • TLR2 Involvement: While a previous study suggested NAT10's role in TLR2-mediated senescence, this study found no significant change in TLR2 expression after NAT10 manipulation, suggesting the NAT10/TLR2 pathway might be specific to adriamycin-induced nephropathy.

Summary updated

Abstract

Acute kidney injury (AKI) is a severe clinical syndrome with high morbidity and mortality, yet its pathogenesis remains incompletely understood, and effective therapeutic strategies are still lacking. In this study, we observed significant upregulation of N-acetyltransferase 10 (NAT10) in the tubular epithelial cells of Cisplatin-induced AKI. Lentivirus-mediated knockdown of NAT10 or treatment with NAT10 inhibitor Remodelin, ameliorated Cisplatin-induced renal dysfunction and tubular injury. Importantly, NAT10 inhibition markedly attenuated cellular senescence in Cisplatin-induced AKI, as evidenced by reduced senescence-associated β-galactosidase (SA-β-gal) activity, downregulation of senescence markers (p53, p21 and γ-H2A.X) and decreased levels of senescence-associated secretory phenotype (SASP) factors (IL-1β, IL-6 and TNF-α). Mechanistically, co-immunoprecipitation assay suggested that NAT10 interacted with DDX17 to regulate its expression. Knockdown or inhibition of NAT10 reduced the protein expression of DDX17 in Cisplatin-injured kidneys. While silencing DDX17 could inhibit Cisplatin-induced senescence in HK-2 cells. Furthermore, we demonstrated that the effects of NAT10 on Cisplatin-induced tubular injury and senescence was dependent on DDX17. Our study revealed a novel mechanism by which NAT10 promoted Cisplatin-induced renal tubular cell senescence via DDX17 upregulation, suggesting that targeting the NAT10/DDX17 signaling axis may offer a potential therapeutic strategy for AKI.
BibTeX
@article{zhu2026nat,
  author = {Yuting Zhu and Wenchao Xu and Cheng Wan and Bowen Deng and Yaru Xie and Bin Yang and Hongyang Jiang and Chun Zhang},
  title = {{NAT10 Promotes Tubular Epithelial Cell Senescence in Cisplatin-Induced Acute Kidney Injury by Regulating DDX17}},
  journal = {International Journal of Biological Sciences},
  year = {2026},
  doi = {10.7150/ijbs.127909},
}
Figure